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To identify the proteins encoded by the porcine adenovirus 3 (PAV-3) E1 region, rabbit antisera were prepared using a
bacterial fusion protein encoding E1A, E1Bsmall, or E1Blarge protein. Sera against E1A, E1Bsmall, and E1Blarge immunoprecipitated
a protein of 35, 23, and 53 kDa, respectively, in in vitro translated and transcribed mRNA and PAV-3 infected cells. To
determine the role of E1 proteins in PAV-3 replication, we constructed vectors with a deletion(s) in the E1 region. Mutant
PAV211, containing deletions in E1A and E3, grew to titers similar to wild-type in VIDO R1 cells (E1A complementing) but not
in swine testicular (ST) cells. No early protein (E1Bsmall, DNA binding protein) expression could be detected in PAV211 infected
ST cells by Western blots. Mutant PAV212, containing deletions in E1Bsmall and E3, grew to wild-type titers in VIDO R1 or ST
cells. These deletions were successfully rescued, resulting in recombinant PAV214, containing deletions in E1A, E1Bsmall, and
E3. However, mutant PAV-3, containing a triple stop codon inserted in the E1Blarge coding sequence, could not be isolated.
Next, we constructed a recombinant PAV216 by inserting the green fluorescent protein gene flanked by a promoter and a
poly(A) in the E1A region of the PAV214 genome. Both PAV214 and PAV216 replicate as efficiently as wild-type in VIDO R1
cells. These results suggested that (a) E1A is essential for virus replication and is required for the activation of other PAV-3
early genes, (b) E1Bsmall is not essential for replication of PAV-3, and (c) E1Blarge is essential for virus replication. Moreover,
the PAV216 vector can be used for the expression of a transgene. © 2001 Elsevier ScienceKey Words: porcine adenovirus-3; E1A; E1Bsmall; E1Blarge; PAV-3 vector.INTRODUCTION
Adenoviruses have been studied for several decades
to probe the process of oncogenesis as they are able to
induce tumors in animals and transform cultured cells
(Darbyshire, 1966; Graham, 1984; Graham et al., 1977;
Houweling et al., 1980; Jones and Shenk, 1979). Since the
first use of human adenovirus as a gene transfer vector
in vivo (Ballay et al., 1985), the utility of adenoviruses as
vectors for gene therapy and vaccination has been the
subject of intense exploration. Several features of adeno-
viruses have made them attractive candidates for use as
gene delivery vectors (Hitt and Graham, 2000; Imler,
1995). Adenoviruses can be grown to high titers in cell
culture and can transduce both dividing and nondividing
cells without inserting themselves into the host cell’s
genome. However, vectors derived from adenoviruses
that naturally infect and replicate in humans may not be
the ideal candidates for human therapeutic purposes.
Since some adenoviruses are endemic in most popula-
tions, there is a risk that the recombinant human adeno-
virus (HAV) vectors could recombine with a preexisting
HAV and generate a replication-competent adenovirus
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68(RCA) (Hehir et al., 1996; Mastrangeli et al., 1996). In
addition, preexisting immunity against HAV can limit the
initial transduction by HAV vectors or might enhance the
cellular immune response against transduced cells. To
overcome some of the problems associated with the use
of human adenovirus as vector, we (Reddy et al., 1999b,
1999c; Zakhartchouk et al., 1998, 1999) and others (Khatri
et al., 1997; Klonjkowski et al., 1997; Michou et al., 1999;
Sheppard et al., 1998; Xu et al., 1997) are exploring the
utility of nonhuman adenoviruses as expression vectors
for animal vaccination and human gene therapy.
Porcine adenoviruses (PAVs) belong to the Mastade-
novirus genus of the Adenoviridae family. Of the five
serotypes identified so far (Derbyshire et al., 1975; Hira-
hara et al., 1990), serotype 3 (PAV-3) could propagate to
high titers in cell culture (Hirahara et al., 1990). Recently,
the transcription map and complete DNA sequence of
the PAV-3 genome were reported (Reddy et al., 1998a,b).
Using the Escherichia coli BJ 5183 recombination system
(Chartier et al., 1996), we have successfully constructed
a full-length infectious clone of the PAV-3 genome (Reddy
et al., 1999a) and recombinant PAV-3s (Reddy et al.,
1999a,b).
Since the E1A region has oncogenic potential (Darby-
shire, 1966; Whyte et al., 1988), recombinant adenovi-
ruses are made replication-defective by the deletion of
the E1A and E1B region. In addition to removing the risk
of transformation (Graham, 1984), deletion of the E1A
region reduces the expression of early and late region
genes, resulting in a lower immune response to adeno-
69E1A 1 E1Bsmall 1 E3 DELETED PAV-3virus vector and long-term expression of the transgene.
Moreover, E1 deleted adenovirus vector provides a sig-
nificant safety profile to the vaccine as it eliminates the
potential for the spread of the vector to nonvaccinated
contacts or to the general environment. Earlier, we con-
structed a replication-defective PAV-3 [E1A (803 bp) and
E3 (597 bp) deletion; Reddy et al., 1999b]. Interestingly,
this virus replicated 2 logs less efficiently than the wild-
type PAV-3 in E1 complementing VIDO R1 cells (fetal
porcine retina cells transformed with HAV-5 E1; Reddy et
al., 1999b). Here, we report the characterization of pro-
teins encoded by the E1 region, construction of a mod-
ified E1A deleted PAV-3, which replicates as efficiently as
wild-type in E1 complementing VIDO R1 cells, and con-
struction of an E1Bsmall deleted PAV-3, which replicates as
efficiently as wild-type in E1 complementing VIDO R1 or
noncomplementing swine testicular (ST) cells. In addi-
tion, we describe the construction of E1A 1 E1Bsmall 1 E3
deleted PAV-3 and use of this vector to express green
fluorescent protein (GFP).
RESULTS
Characterization of PAV-3 E1 proteins
In order to identify and characterize the proteins en-
coded by the E1 region of PAV-3, we made anti-E1A,
anti-E1Bsmall, and anti-E1Blarge sera by immunizing rabbits
with 300 mg of gel-purified glutathione S-transferase
(GST)-protein fusions. Sera collected after the final boost
were analyzed by in vitro transcription and translation
assays to determine specificity of the antibodies in the
rabbit sera. The plasmids pSP64-PE1A, pSP64-PE1Bs,
and pSP64-PE1B1 were generated in which the coding
sequence of E1A, E1Bsmall, and E1Blarge, respectively, was
placed downstream of the SP6 promoter. In vitro trans-
lation of pSP64-PE1A RNA resulted in the synthesis of a
FIG. 1. Immunoprecipitation of proteins synthesized by in vitro tran-
scription and translation of plasmids. [35S]Methionine-labeled, in vitro
transcribed and translated pSP64-PE1A (lanes 7, 9), pSP64-PE1Bs
(lanes 4, 6), pSP64-PE1B1 (lanes 1, 3), and pSP64polyA (lanes 2, 5, 8)
products before (lanes 3, 6, 9) and after immunoprecipitation with
anti-E1A (lanes 7, 8), anti-E1Bsmall (lanes 4, 5), and anti-E1Blarge (lanes 1,
2) were separated on 10% SDS–PAGE gels under reducing conditions.
The positions of the molecular weight markers are shown to the left of
the panel.polypeptide of 35 kDa (Fig. 1, lane 9) which was recog-nized by anti-E1A serum (Fig. 1, lane 7). In vitro transla-
tion of pSP64-PE1Bs RNA resulted in the synthesis of a
polypeptide of 23 kDa (Fig. 1, lane 6) which was recog-
nized by anti-E1Bsmall serum (Fig. 1, lane 4). Similarly, in
vitro translation of pSP64-E1B1 RNA resulted in the syn-
thesis of a polypeptide of 53 kDa (Fig. 1, lane 3) which
was recognized by anti-E1Blarge serum (Fig. 1, lane 1).
These proteins were not immunoprecipitated with anti-
E1A serum (Fig. 1, lane 8), anti-E1Bsmall serum (Fig. 1, lane
5), or anti-E1Blarge serum (Fig. 1, lane 2) from reactions in
which pSP64polyA (negative control plasmid) was trans-
lated in vitro.
To further characterize the proteins and to confirm the
specificity of the antisera, radioimmunoprecipitation as-
says (RIPAs) were performed. Anti-E1A serum detected a
protein of 35 kDa in PAV-3 infected cells (Fig. 2A, lanes 1
and 2) but not in mock-infected cells (Fig. 2A, lane 3). The
35-kDa protein was detected at 6 h (Fig. 2A, lane 1) and
24 h (Fig. 2A, lane 2) postinfection. Anti-E1Bsmall detected
a protein of 23 kDa in PAV-3 infected cells (Fig. 2B, lanes
1 and 2) but not in mock-infected cells (Fig. 2B, lane 3).
The 23-kDa protein was detected at 6 h (Fig. 2B, lane 1)
and 24 h (Fig. 2B, lane 2) postinfection. Similarly, anti-
E1Blarge serum detected a protein of 53 kDa in PAV-3
infected cells (Fig. 2C, lanes 1 and 2) but not in mock-
infected cells. The 53-kDa protein was detected at 6 h
(Fig. 2C, lane 1) and 24 h (Fig. 2C, lane 2) postinfection.
Generation of PAV-3 E1 deletion/insertion mutants
Taking advantage of homologous recombination in E.
coli strain BJ5183, initially we constructed three full-
length plasmids: (a) pFPAV211, containing deletions in
the E1A (nt 530–1230) and E3 (nt 28,112–28,709) regions
(Fig. 3A); (b) pFPAV212, containing deletions in the
E1Bsmall (nt 1460–1820) and E3 (nt 28,112–28,709) regions
(Fig. 3B); and (c) pFPAV507, containing a TPS (triple
phase stop) codon in E1Blarge (nt 2190) and deletion of the
E3 (nt 28,112–28,709) region (Fig. 3C). The PacI digested
pFPAV211 or pFPAV212 plasmid DNAs were transfected
FIG. 2. In vivo immunoprecipitation of E1 proteins. Proteins from the
lysates of [35S]methionine–cysteine-labeled mock-infected (lane 3) or
PAV3 infected (lane 1, 6 h postinfection; lane 2, 24 h postinfection) VIDO
R1 cells were immunoprecipitated with anti-E1A serum (A), anti-E1Bsmall
serum (B), or anti-E1Blarge serum (C) and separated on 10% SDS–PAGE
under reducing conditions. The positions of the molecular weight
markers are indicated to the left of each panel.
oly(A)
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10–14 days. However, repeated transfection of VIDO R1
cells with PacI digested pFPAV507 DNA did not produce
any cytopathic effects. The transfected cell monolayers
were collected and freeze–thawed, and recombinant vi-
ruses were plaque-purified and propagated in VIDO R1
cells. The recombinant PAVs were named PAV211 (E1A 1
E3 deletion) and PAV212 (E1Bsmall 1 E3 deletion). The viral
DNA was isolated from virus infected cells by the Hirt
extraction method (Hirt, 1967) and analyzed by agarose
gel electrophoresis after digestion with restriction en-
zymes. Since PAV211 and PAV212 genomes contain an
additional SpeI site in place of the E1A or E1Bsmall re-
gions, respectively, the recombinant viral DNAs were
digested with SpeI. As seen in Fig. 4A, compared with
wild-type PAV-3 (lane 3), the PAV211 (lane 1) and PAV212
(lane 2) genomes contain an additional expected band of
530 and 1460 bp, respectively.
The ability of PAV211 and PAV212 to produce E1A and
E1Bsmall or DNA binding protein (DBP) was tested by
Western blot analysis of these proteins from lysates of
virus infected ST cells using PAV-3 E1A-, E1Bsmall-, or
DBP-specific antisera (Zhou et al., in press,a). Wild-type
PAV-3 (Fig. 5C, lane 3) or PAV212 (Fig. 5C, lane 1) infected
cells produced an E1A protein of 35 kDa. No such protein
was detected in PAV211 (Fig. 5C, lane 2) infected cells.
Similarly, wild-type PAV-3 (Fig. 5B, lane 3) and PAV212
(Fig. 5B, lane 1) produced a DBP of 50 kDa. No such
protein was detected in PAV211 (Fig. 5B, lane 2) infected
cells. In addition, wild-type PAV-3 (Fig. 5A, lane 3) in-
fected cells produced an E1Bsmall protein of 23 kDa (Fig.
FIG. 3. Schematic representation of full-length genomic DNA in plasm
plasmid pFPAV214; (E) plasmid pFPAV216. The origin of DNA sequence
plasmid DNA (broken line). HCMV promoter (n ); GFP gene (z); BGH p5B, lane 3). However, no such protein was detected inPAV211 (Fig. 5A, lane 2) or PAV212 (Fig. 5A, lane 1)
infected cells.
Construction of E1A 1 E1Bsmall 1 E3 deletion mutant
of PAV-3
In order to increase the insertion capacity of the PAV-3
vector, a full-length plasmid pFPAV214 (Fig. 3D) carrying
deletions in E1A (nt 530–1230), E1Bsmall (nt 1460–1820),
and E3 (nt 28,112–28,709) was constructed by homolo-
gous recombination in E. coli BJ5183. Transfection of
VIDO R1 cells with PacI digested plasmid pFPAV214 DNA
produced cytopathic effects in 7–10 days. The recombi-
nant PAV-3, named PAV214, was plaque-purified and ex-
panded in VIDO RI cells. The viral DNA was extracted
and analyzed by agarose gel electrophoresis after diges-
tion with NheI. As seen in Fig. 4B, the wild-type PAV-3 had
a fragment of 1.430 kb (lane 2) that was missing in PAV214,
which instead had a fragment of 0.737 kb (lane 1).
Construction of E1A 1 E1Bsmall 1 E3 deleted PAV-3
expressing GFP
In order to determine whether the PAV214 genome
(E1A, E1Bsmall, and E3 deleted) is useful for expression of
foreign genes, we constructed recombinant PAV-3 ex-
pressing GFP. The full-length GFP gene [flanked by the
human cytomegalovirus (HCMV) promoter and bovine
growth hormone (BGH) poly(A) signal] was inserted into
the E1A region of pFPAV214 in the same transcriptional
orientation as E1 (using the homologous recombination
machinery of E. coli), creating plasmid pFPAV216 (Fig.
) plasmid pFPAV211; (B) plasmid pFPAV212; (C) plasmid pFPAV507; (D)
follows: BAV-3 genome (open box); ITR (filled box); AmpR gene (arrow);
( ). The plasmid maps are not drawn to scale.ids. (A
s is as3E). The PacI digested pFPAV216 DNA was transfected
h geno
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The viral DNA was extracted and analyzed by agarose
gel electrophoresis after digestion with restriction en-
zyme. Since there is an AseI site in the CMV promoter,
insertion of the GFP transcription cassette in the E1A
region of the PAV214 genome was confirmed by AseI
digestion. As seen in Fig. 4C, wild-type PAV-3 had a
fragment of 1.274 kb (lane 1) that is missing in PAV216,
which instead had two fragments of 0.584 and 1.739 kb
(lane 2). Expression of GFP was confirmed by Western
blot using GFP-specific polyclonal antibody (Clontech).
As seen in Fig. 6, the GFP could be detected in PAV216
FIG. 4. Restriction enzyme analysis of recombinant PAV-3 genome. (A
1), PAV212 (lane 2), or wild-type PAV-3 (lane 3) and digested with SpeI. S
from VIDO R1 cells infected with PAV214 (lane 1) or wild-type PAV-3 (la
(C) The viral DNAs were extracted from VIDO R1 cells infected with PAV2
(M) are shown in basepairs. (D) Schematic representation of full-lengtinfected VIDO R1 cells at 24 (lane 4) and 48 hpi (lane 5).The size of GFP expressed in cells infected with virus is
similar to that of purified GFP (lane 2), which is 28 kDa.
No such protein could be detected in mock-infected cells
(lane 1) or wild-type PAV-3 infected cells (lane 3).
Growth kinetics of PAV211, PAV212, PAV214, and
PAV216
In order to determine the importance of E1A and
E1Bsmall in viral replication, the ability of mutant viruses to
grow in VIDO R1 and ST cells was compared to that of
wild-type PAV-3. Virus infected cells were harvested at
ral DNAs were extracted from VIDO R1 cells infected with PAV211 (lane
arkers (M) are shown in basepairs. (B) The viral DNAs were extracted
nd digested with NheI. Sizes of markers (M) are shown in basepairs.
e 2) or wild-type PAV-3 (lane 1) and digested with AseI. Sizes of markers
mes of PAV-3s depicting selected restriction enzyme sites.) The vi
izes of m
ne 2) a
16 (landifferent times postinfection and freeze–thawed three
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DBP detection assay (Zhou et al., in press).
Wild-type PAV-3 titer was 5.2 3 107 infectious units
(IU)/ml at 72 h postinfection (hpi) on VIDO R1 cells. The
titers of mutant viruses were between 2 3 107 and 3.2 3
107 IU/ml, values which are quite similar to that of wild-
type PAV-3 virus. Therefore, PAV vectors with deletions in
E1A and/or E1Bsmall did not have any effect on the ability
of PAV-3 to propagate in VIDO R1 cells (E1 complement-
ing cell line) (Fig. 7A). In contrast, we could not observe
any progeny virus production in PAV211, PAV214, and
PAV216 infected ST cells (E1 noncomplementing). The
virus titers at 72 hpi were never more than 2 3 105 IU/ml,
which was lower than the amount of input virus (Fig. 7B).
All of these three viruses carry deletions in the E1A
region. Most notably, mutant virus PAV212 that carried
deletions in the E1Bsmall region was able to grow both in
complementing and noncomplementing cell lines (Figs.
7A and 7B). At 72 hpi the production of PAV212 in VIDO
R1 and ST cells was 3.3 3 107 and 3.9 3 107 IU/ml,
respectively.
DISCUSSION
Adenoviruses have been shown to be excellent mam-
malian cell expression vectors, which are currently con-
FIG. 5. Western blot analysis of PAV-3 protein expression in mutant
infected cells. Proteins from wild-type PAV3 (lane 3), PAV211 (lane 2), or
PAV212 (lane 1) infected ST cells were separated by 12.5% SDS–PAGE
under reducing conditions and transferred to nitrocellulose. The sep-
arated proteins were probed in Western blots by anti-E1A (C), anti-
E1Bsmall (A), or anti-DBP (B). The positions of the molecular weight
markers are shown to the left of each panel.
FIG. 6. Western blot analysis of GFP expression. Proteins from
purified GFP (lane 2) or mock (lane 1), wild-type PAV-3 (lane 3), and
PAV216 (lane 4 and 5) infected VIDO R1 cells harvested at 24 hpi (lane
3, 4) and 48 hpi (lane 5) were separated by 10% SDS–PAGE under
reducing conditions and transferred to nitrocellulose. The separated
proteins were probed Western blots by anti-GFP polyclonal antibody.sidered as one of the most efficient viral vectors for gene
delivery in vivo. We (Reddy et al., 1999a,b,c; Zakhartchouk
et al., 1998, 1999) and others (Hofmann et al., 1999; Khatri
et al., 1997; Klonjkowski et al., 1997; Michou et al., 1999;
Sheppard et al., 1998; Xu et al., 1997; Xu and Both, 1998)
are extending the range of adenoviral vectors for use in
vaccination and human gene therapy by developing ad-
enoviruses of animal origins as vectors. In addition,
these species-specific adenoviral vectors are ideal can-
didates for developing novel recombinant vaccines for
animals. Previously, we have reported the development
of replication-competent (Reddy et al., 1999a) and repli-
cation-defective (Reddy et al., 1999b) PAV-3 vectors. In
this report, we describe the characterization of E1 pro-
teins. In addition, we describe the development of E1A 1
E3, E1Bsmall 1 E3, and E1A 1 E1Bsmall 1 E3 deleted PAV-3
vectors and demonstrate that E1A 1 E1Bsmall 1 E3 de-
leted PAV-3 can be used for the expression of foreign
genes.
The E1 mRNAs of PAV-3 (Reddy et al., 1998a) have the
FIG. 7. Virus titers of recombinant and wild-type PAV-3. Near-conflu-
ent monolayers of VIDO R1 (A) or ST (B) cells were infected with
recombinant or wild-type PAV-3. At different time points postinfection,
the cell pellets were freeze–thawed and virus was titrated on VIDO R1
cells as described in the text. PAV211 (}), PAV212 (h), PAV214 (),
PAV216 (), PAV-3 wt. (F).potential to code for three proteins including 229R (E1A),
73E1A 1 E1Bsmall 1 E3 DELETED PAV-3202R (E1Bsmall), and 474R (E1Blarge). The 229R protein,
synthesized as a 35-kDa protein in PAV-3 infected cells
shows homology to the CR2 and CR3 domains of the E1A
protein of HAV-2 (Zantema and Van Der Eb, 1995), which
are involved in the efficient transcription and activation of
other promoter elements in the genome of adenovirus.
The 202R protein, produced as a 23-kDa protein in PAV-3
infected cells, shows homology to the central and amino-
terminal regions of the E1Bsmall protein of HAV-2 (White et
al., 1992), which are important in the anti-apoptotic func-
tion of the protein. The 474R protein, synthesized as
53-kDa protein in PAV-3 infected cells, shows homology
to domains of the 55K protein of HAV-5 (Rubenwolf et al.,
1997), which are involved in protein–protein interactions.
However, despite some amino acid homologies among
E1 proteins of different adenoviruses, functional dissim-
ilarities have been reported (Abrahamsen et al., 1997;
Ying et al., 1998).
Recombinant PAV211 lacking the E1A (nt 530–1230)
and part of E3 (nt 28,112–28,709) coding regions grew to
titers similar to wild-type PAV-3 in VIDO R1 cells. In
contrast, recombinant PAV201 containing deletions in
E1A (nt 407–1210) and E3 (nt 28,112–28,709) grew to titers
of two logs less than wild-type PAV-3 in E1 expressing
VIDO R1 cells (Reddy et al., 1999b). This suggests that
deletion of 123 bp (nt 407–530) results in the reduced
yield of PAV201 in VIDO R1 cells. It is possible that this
region may contain some enhancer sequences, which
may affect the early viral gene expression. Alternatively,
it is possible that this region may contain some packag-
ing signal(s), which may affect the efficiency of virion
DNA encapsidation. Further experiments are needed to
support or refute these speculations.
Recombinant PAV211 virus lacking the E1A (nt 530–
1230) and part of E3 (nt 28,112–28,709) coding regions
failed to produce infectious progeny virus in E1 nonex-
pressing ST cells. In addition, no expression of early
region genes was detected in PAV211 virus infected ST
cells. These results confirm our earlier observation
(Reddy et al., 1999b) and further suggest that the E1A
protein is required for the transactivation of other PAV-3
early genes. Similar results have been reported for the
E1A protein of BAV-3 (Zhou et al., 2001), HAV-5 (Berk,
1986), or CAV-2 (Klonjkowski et al., 1997; Kremer et al.,
2000). However, E1A of MAV-1 is not required for the
transactivation of other early genes (Ying et al., 1998).
It is possible that PAV211 virus detected in ST cells is
the progeny virus produced at low levels. However, no
expression of early region genes was detected in PAV211
virus infected ST cells, which is thought to be required for
the production of progeny virus. Alternatively, it is possi-
ble that the E1A gene has been restored through PAV211
virus stock preparation in the VIDO R1 cells by homolo-
gous recombination. However, acquisition of the E1A
gene by homologous recombination is a very remote
possibility as VIDO R1 cells contain the HAV-5 E1 region
DNA, which does not show any significant similarity tothe nucleotide sequence of the E1 region retained in
PAV211.
Recombinant PAV212 containing deletions in E1Bsmall
(nt 1460–1820) and part of E3 (nt 28,112–28,709) grew to
titers similar to wild-type PAV-3 in E1 expressing VIDO R1
cells. In the absence of E1Bsmall, both early and late
region genes were expressed. In addition, PAV212 grew
to titers similar to wild-type PAV-3 in E1 nonexpressing
ST cells. These results suggest that the E1Bsmall gene
product does not impose any significant regulatory ef-
fects on viral growth or on the expression of the viral
early genes in ST cells. Earlier studies using E1Bsmall
mutants of HAV-5 (Hu and Hsu, 1997; White and Stillman,
1987) and BAV-3 (Zhou et al., 2001) have suggested that
the requirement of E1Bsmall protein for viral replication
depends on the type of cultured cell line used. Although
we have not found a significant difference in the replica-
tion of PAV212 in the few available porcine cell lines (data
not shown), nevertheless we need to test more porcine
cell lines.
The construction of PAV214 was the first step toward
the development of a PAV-3 vector containing deletions
in the E1A, E1Bsmall, and E3 regions. PAV214 contains a
700-bp E1A deletion (nt 530–1230), a 360-bp E1Bsmall
deletion (nt 1460–1820), and a 597-bp E3 deletion (nt
28,112–28,709) and therefore should be able to accom-
modate 3.5-kb foreign DNA, an improvement over the
capacity of currently available PAV-3 vector (Reddy et al.,
1999b). The construction of PAV216 further demonstrated
the feasibility of using this vector system for foreign gene
expression. These viruses could be propagated in VIDO
R1 cells with growth kinetics similar to those of wild-type,
indicating that neither the extended deletion (E1A,
E1Bsmall, E3) nor foreign gene insertion alters the viability
of the viruses.
It has been suggested that E1B may not be required
for complementation of E1A and E1B deleted HAV-5 (Im-
ler et al., 1996). However, repeated attempts to extend
the deletion further in the E1 region proved futile as we
could not rescue a PAV-3 vector with either gene deletion
or insertional inactivation (TPS codon) of the E1Blarge
gene even in VIDO R1 (E1 complementing) cells. Simi-
larly, E1B deleted HAV-7a could not be isolated using 293
(E1 complementing; Abrahamsen et al., 1997) cells. It is
possible that the human E1B 55-kDa protein does not
complement the porcine E1Blarge defect of PAV-3. Since
the E1Blarge gene product of HAV-5 interacts with both
host and viral proteins, the absence of PAV-3-specific
E1Blarge interactions in VIDO R1 cells (fetal porcine retina
cells transformed with HAV-5 E1) may be responsible for
not isolating E1Blarge defective PAV-3.
MATERIALS AND METHODS
Cells and viruses
VIDO R1 (Reddy et al., 1999b) and ST cells were grown
and maintained in minimum essential medium (MEM)
74 ZHOU AND TIKOOsupplemented with 10% fetal bovine serum (FBS). The
mutant PAV-3 and wild-type PAV-3 (strain 6618) were
propagated and titrated in VIDO R1 cells (Reddy et al.,
1999b).
GST fusion and antibody production
The plasmid pE1A was created by amplifying part of
E1A (nt 556–1222) by PCR and ligating in-frame to the
GST gene in plasmid pGEX-5X-3. To create plasmid
pE1Bs, part of the E1Bsmall ORF (nt 1470–2070) was am-
plified by PCR and ligated in-frame to the GST gene in
plasmid pGEX-5X-3. The plasmid pE1B1 was created by
amplifying the complete E1Blarge ORF (nt 1831–3250) by
PCR and ligated in-frame to the GST gene in plasmid
pGEX-5X-3. The junctions of the sequences encoding
GST–E1A, GST–E1Bsmall, or GST–E1Blarge were sequenced
to ensure that the coding domains are in-frame. The
competent E. coli strain BL121 was transformed with
pE1A, pE1Bs, or pE1B1 plasmids. The fusion protein(s)
was induced by addition of 0.1 M isopropyl-b-D-thiogal-
actoside and purified using sodium dodecyl sulfate
(SDS)–polyacrylamide gel electrophoresis (PAGE). Rab-
bits were immunized subcutaneously with 300 mg of
gel-purified GST–E1A, GST–E1Bsmall, or GST–E1Blarge fu-
sion proteins in Freund’s complete adjuvant followed by
three injections in Freund’s incomplete adjuvant at
4-week intervals.
In vitro transcription and translation
The complete coding regions of E1A, E1Bsmall, and
E1Blarge were individually cloned into the SmaI site of
plasmid pSP64 polyA, creating plasmids pSP64-PE1A,
pSP64-PE1Bs, and pSP64-PE1B1, respectively. The plas-
mid DNAs were transcribed and translated in vitro by
using a rabbit reticulocyte lysate-coupled transcription–
translation system in the presence of 50 mCi of [35S]me-
thionine. The in vitro translated proteins were analyzed
with or without immunoprecipitation with the protein-
specific polyclonal rabbit serum.
Construction of PAV-3 recombinant plasmids
The recombinant plasmid vectors were constructed by
standard procedures using restriction enzymes and
other DNA modifying enzymes.
Construction of plasmid pFPAV211. A 9.225-kb XhoI
fragment [containing vector backbone plus the left (nt 1
to 4159) and right (nt 31,053 to 34,094) termini of the PAV-3
genome] isolated from plasmid pFPAV200 (Reddy et al.,
1999a) was religated, creating plasmid pPAVXhoIRL. Nu-
cleotide numbers of the PAV-3 genome referred to in this
report are given according to GenBank Accession No.
AF083132. To delete the E1A region, the PAV-3 genome
between nt 0 and 531 was amplified by using primers
YZ-13, 59-ATA GGC GTA TCA CGA GGC-39, and YZ-14,
59-CTG GAC TAG TCT GTT CCG CTG AGA GAA AAC-39,
and plasmid pPAVXhoIRL DNA as a template in a PCR.The PAV-3 genomic DNA between nt 1231 and 1529 was
amplified by using primers YZ-15, 59-GTG GAC TAG TCT-
CAT GCA GCG AACAAC C-39, and YZ-16, 59-GTA CTA
TCA CCT TCC TAA GG-39, and plasmid pPAVXhoIRL DNA
as a template in a PCR. The product of the first PCR was
digested with BamHI–SpeI and gel-purified. The second
PCR product was digested with SpeI–Bsu36 and gel-
purified. The two gel-purified fragments were cloned into
BamHI and Bsu36 digested plasmid pPAVXhoIRL in a
three-way ligation. The resulting plasmid, pYZ20, carried
a 700-bp (nt 530 to 1230) deletion in the E1A region and
an engineered SpeI site. The recombinant PAV-3 genome
containing deletions in the E1A and E3 regions (pF-
PAV211) was generated by homologous DNA recombina-
tion in E. coli BJ 5183 between XhoI linearized pYZ20 and
genomic DNA of PAV-3 E3 (Reddy et al., 1999a; Fig. 3A).
Construction of plasmid pFPAV212. A 633-bp fragment
(nt 827 to 1460) isolated by PCR amplification (using
oligonucleotides YZ-17, 59-ACA GTA ATG AGG AGG ATA
TC-39, and YZ-18, 59-TAG GAC TAG TCC CAC AGA AAA
AGA AAA GG-39, as primers and plasmid pPAVXhoIRL as
a template) was digested with EcoRV–SpeI and gel-
purified. A 403-bp fragment (nt 1820 to 2223 of the PAV-3
genome) isolated by PCR amplification (using oligonu-
cleotides YZ-19, 59-ATG GAC TAG TCT TCT GGT GCC
GCC ACT A-39, and YZ-20, 59-CCT AAT CTG CTC AAA
GCT G-39, as primers and plasmid pPAVXhoIRL DNA as
a template) was digested with SpeI–Eco47III and gel-
purified. A 6.947-kb XhoI–StuI fragment of plasmid
pPAVXhoIRL was blunt end repaired with T4 polymerase
and religated to create plasmid pYZ9a. The two gel-
purified DNA fragments were ligated to EcoRV–Eco47III
digested plasmid pYZ9a in a three-way ligation. The
resulting plasmid pYZ21 contains a 360-bp deletion (nt
1460–1820) in the E1Bsmall region and an engineered SpeI
site. Finally, a 5.506-kb HpaI–AspI fragment of pYZ21 was
ligated to the 3.374-kb HpaI–AspI fragment of pPAVX-
hoIRL to create plasmid pYZ21a. The recombinant PAV-3
genome containing deletions in the E1Bsmall and the E3
regions (pFPAV212) was generated by homologous DNA
recombination in E. coli BJ5183 between XhoI linearized
pYZ21a and the genomic DNA from PAV E3 (Reddy et al.,
1999a; Fig. 3B).
Construction of plasmid pFPAV507. Plasmid pPAVX-
hoIRL was digested partially with Eco47III and ligated to
the SpeI linker (TPS codon). Plasmid pYZ9 containing the
SpeI linker inserted in the E1Blarge ORF was selected. The
recombinant PAV-3 genome containing a deletion in E3
and an insertion in E1Blarge (pFPAV507) was generated by
homologous DNA recombination machinery in E. coli
BJ5183 between XhoI linearized pYZ9 and the genomic
DNA from PAV E3 (Reddy et al., 1999a; Fig. 3C).
Construction of plasmid pFPAV214. A 0.591-kb BamHI–
AseI fragment was excised from plasmid pYZ20 and
ligated to 5.309-bp BamHI–AseI (partial) digested pYZ21
to create plasmid pYZ36. Finally, a 4.813-kb HpaI–AspI
fragment excised from plasmid pYZ36 was ligated to the
75E1A 1 E1Bsmall 1 E3 DELETED PAV-33.373-kb HpaI–AspI fragment of plasmid pPAVXhoIRL to
create plasmid pYZ37. The recombinant PAV-3 genome
containing deletions in the E1A, E1Bsmall, and E3 region
(pFPAV214) was generated by homologous recombina-
tion in E. coli BJ5183 between XhoI linearized plasmid
pYZ37 and genomic DNA from PAV E3 (Reddy et al.,
1999a; Fig. 3D). The full-length plasmid pFPAV214 con-
tained a 727-bp (nt 530–1230) deletion in E1A, a 360-bp
(nt 1460–1820) deletion in E1Bsmall, and a 597-bp (nt
27,405–28,112) deletion in E3.
Construction of plasmid pFPAV216. Plasmid pYZ20
was digested with SpeI, blunt end repaired with T4 poly-
merase, and ligated to PmeI linker (GTTTAAAC) creating
plasmid pYZ39. A 1.424-kb AseI fragment of plasmid
pYZ39 was isolated and ligated to the 6.774-kb AseI
fragment of pYZ37 to create plasmid pYZ40. Finally, a
1.730-kb NruI–PvuII fragment [containing the HCMV im-
mediate-early promoter, GFP gene, and BGH poly(A) sig-
nal] was excised from plasmid pYZ41a (Zhou et al.,
manuscript in preparation) and ligated to PmeI digested
pYZ40 to create plasmid pYZ42. The recombinant PAV-3
genome containing the GFP expression cassette inser-
tion in the E1A region of the E1A, E1Bsmall, and E3 deleted
regions was generated by homologous recombination in
E. coli BJ5183 between XhoI linearized pYZ42 and
genomic DNA from PAV E3 (Reddy et al., 1999a; Fig. 3E).
Transfection and isolation of PAV-3 mutant viruses
VIDO R1 cell monolayers seeded in a 6-well plate
were transfected with 5–10 mg of PacI digested pF-
PAV211, pFPAV212, pFPAV214, pFPAV216, or pFPAV507
recombinant plasmid DNAs using the Lipofectin method
(Gibco BRL). After 7–10 days of incubation at 37°C, the
transfected cells showing 50% cytopathic effect were
collected and freeze–thawed three times. Finally, the
recombinant virus was plaque-purified and expanded in
VIDO R1 cells.
Virus growth curve
VIDO R1 or ST cells were infected with mutant or
wild-type PAV-3 at an m.o.i. of 5. The infected cells,
harvested at the indicated times postinfection, were
lysed in the infection medium by three rounds of freez-
ing–thawing. Virus titers were determined by serial dilu-
tion infections of VIDO R1 cells followed by immunohis-
tochemical detection of DNA binding protein (Zhou et al.,
in press). Titers were expressed as infectious units in
which 1 IU was defined as one positive stained focus at
3 days postinfection.
Western blot
For Western blot, about 1 3 106 VIDO R1 or ST cells
were infected with recombinant or wild-type PAV-3 at an
m.o.i. of 5. At the indicated times postinfection, the cells
were collected and lysed in 100 ml of RIPA buffer (0.15 M
NaCl, 50 mM Tris–HCl, pH 8.0, 1% NP-40, 1% deoxy-cholate, 0.1% SDS). Proteins were resolved on SDS–
PAGE under reducing conditions and electrotransferred
to a nitrocellulose membrane (Bio-Rad). Nonspecific
binding sites were blocked with 1% bovine serum albu-
min fraction V, and the membrane was probed with the
protein-specific rabbit polyclonal serum. The membrane
was washed and exposed to goat anti-rabbit IgG conju-
gated to alkaline phosphatase and developed using an
alkaline phosphatase color development kit (Bio-Rad).
Radioimmunoprecipitation
VIDO R1 cells in 6-well plates were infected with
wild-type PAV-3 at an m.o.i. of 5. After virus adsorption for
1 h, the cells were incubated in MEM containing 5% FBS.
At different times postinfection, the cells were incubated
in methionine–cysteine-free MEM for 1 h before being
labeled with [35S]methionine–cysteine (100 mCi/well). Af-
ter 6 or 24 h of labeling, the cells were harvested.
Proteins were immunoprecipitated from cells lysed with
modified RIPA buffer and analyzed by SDS–PAGE as
described previously (Tikoo et al., 1993).
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